AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05745662 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-15)
Study NCT05148026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin + RCA first
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
Study NCT05148026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin first
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
Study NCT06031753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
Study NCT05059899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
Study NCT06142084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
Study NCT05671809 — intervention group
Intervention type: OTHER
Intervention: NCRT with surgery, or NCT with surgery, or surgery
Description: The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
Study NCT05579067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.
Description: The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
Study NCT05579067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction using an autograph of Hamstrings muscle tendons.
Description: The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection
Description: Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection
Description: Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants
Description: Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants
Description: Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants
Description: A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
Study NCT05047445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants
Description: A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
Study NCT06161896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: Analysis of microbiome, mutations, alterations in body composition and lifestyle
Study NCT04676256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early vitrectomy
Description: Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Study NCT04676256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Description: Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Study NCT05410756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Voice Quality and Function
Description: An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
Study NCT04865874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV-GDT
Description: fluid-therapy based on PPV monitoring
Study NCT04865874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero-balance
Description: fluid-therapy based on urinary output balance
Study NCT04884451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Diet and physical activity modification and behavioral approach
Study NCT05987488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ShigETEC live, attenuated, oral vaccine
Description: Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses.
Study NCT05987488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart.
Study NCT05541588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral nerve block
Description: ultrasound guided nerve block
Study NCT06184282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO
Description: MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Study NCT06184282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Study NCT06142084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, high bioavailability
Description: Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
Study NCT06142084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
Study NCT06142084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein, high bioavailability
Description: Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
Study NCT06142084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
Study NCT06387017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: blood collection
Study NCT06387017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stool collection
Description: stool collection
Study NCT05365854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar Recruitment Maneuver (ARM)
Description: When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order.
Study NCT05832554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal airway
Description: nasopharyngeal airway
Study NCT05832554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral airway
Description: oropharyngeal airway
Study NCT04879524 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous infracoccygeal Botulinum toxin injection to puborectalis
Description: The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete.
Study NCT04122456 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
Study NCT04122456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
Study NCT04774250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100Mg Cap
Description: ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
Study NCT04774250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
Study NCT04782791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOX
Description: The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
Study NCT04782791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
Study NCT04782791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
Study NCT04782791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
Study NCT06387017 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: low dose CT scan
Description: low dose CT scan evaluation
Study NCT04514783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Debridement with Debritom+ micro water jet device
Description: Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)
Study NCT04514783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Debridement with
Description: Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)
Study NCT06007079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device
Description: Wearable monitor
Study NCT06306560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab
Description: adebrelimab IV
Study NCT06306560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib
Description: famitinib PO
Study NCT05470257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: Application of fiberglass long arm cast.
Study NCT06518850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
Study NCT06518850 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rifaximin
Description: Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
Study NCT06371183 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscope
Description: Endoscopy for lower GIT
Study NCT05232370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor
Description: Angiotensin-converting enzyme inhibitors after Kidney Transplant
Study NCT05232370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin receptor blockers after Kidney Transplant
Study NCT05324865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
Study NCT06306560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: chemotherapy IV
Study NCT06080230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participants in the 8-week program
Description: Psychological resilience program based on positive psychotherapy was applied to nurses
Study NCT05011279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Move Together app/Garmin Activity Tracker
Description: * The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time.
Study NCT05765773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS
Description: 200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
Study NCT05061680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic short duration papillary large balloon dilation
Description: During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
Study NCT05778383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
Study NCT05046444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
Study NCT05009433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training program for pregnant women
Description: Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
Study NCT05009433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training program for pregnant women
Description: Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman.
Study NCT05009433 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard obstetric care with extended education on healthy lifestyle
Description: Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.